Skip to search formSkip to main contentSkip to account menu

sibenadet

National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AR C68397AAViozan

Broader (1)

Thiazoles
sibenadet hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The discovery of AZD 3199 A new inhaled ultra-long acting 2 receptor agonist with rapid onset of action
A series of dibasic des-hydroxy 2 receptor agonists has been prepared and evaluated for potential as inhaled ultra-long acting… 
2011
2011
Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
2007
2007
Long-term use ofViozanTM ( sibenadet HCI ) in patients with chronic obstructive pulmonary disease : results of a I-year study
Viozan TM (sibenadet HCI,AR-C68397AA) is a novel dual D 2 dopamine receptor, 132-adrenoceptor agonist that has been investigated… 
2006
2006
Progress in the Development of Inhaled, Long-Acting β2-Adrenoceptor Agonists
2005
2005
Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists.
In addition to breathlessness and cough, excessive mucus production is one of the main symptoms of chronic obstructive pulmonary… 
2004
2004
Suppression of histamine-induced tachypnoea in the rhesus monkey by sibenadet: no role for dopamine D2 receptors.
1. Sibenadet (Viozan), a dual dopamine D(2)/beta(2)-adrenoceptor agonist, suppresses histamine-induced tachypnoea in the dog by… 
2003
2003
The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)